Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADFAST study of TX200-TR101 in living donor kidney transplant recipients
NL-OMON60793Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Mar 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TX200 in kidney allograft rejection, sponsored by Sangamo Therapeutics. Primary endpoint: Short-term safety and tolerability. Started Mar 2021; status: completed.
02
Drugs
TX200
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON60793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60793.